Label expansion for Lymphoseek

|By:, SA News Editor

The FDA approves the use of Navidea Biopharmaceuticals' (NAVB -7.4%) radioactive imaging agent Lymphoseek for use in sentinel lymph node biopsies. Sentinel lymph nodes are those closest to a primary tumor for cancer. This new indication allows for more limited lymph node surgery in patients with sentinel nodes negative for cancer.

Last year, the regulator cleared the product as an aide in the identification of lymph nodes closest to a primary tumor in patients with breast cancer or melanoma.